One of the primary uses of the GastroPanel is to assess the risk of developing gastric cancer and other gastrointestinal disorders, such as atrophic gastritis and peptic ulcers. By measuring levels of pepsinogen I and II, the test can identify individuals with gastric mucosal atrophy, which is a known precursor to gastric cancer. Additionally, elevated levels of gastrin-17 may indicate an increased risk of developing gastric tumours, while the presence of Helicobacter pylori antibodies suggests an active or past infection with the bacterium, which is associated with gastritis and peptic ulcer disease.
The GastroPanel is also useful for monitoring patients with known gastrointestinal conditions, such as those with a history of Helicobacter pylori infection or autoimmune gastritis. By regularly assessing biomarker levels, healthcare providers can evaluate disease progression, monitor treatment efficacy, and identify individuals at increased risk of developing complications.
Compared to traditional diagnostic methods, such as endoscopy and biopsy, the GastroPanel offers several advantages, including its non-invasive nature, ease of administration, and ability to provide comprehensive information about gastric health from any clinical setting.
